Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Opt...
January 25 2018 - 4:05PM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in
the development of restorative cell therapies, today announced the
closing of its previously announced underwritten registered direct
offering of 2,691,494 shares of its common stock, which includes
351,064 shares sold in connection with the exercise in full by the
underwriter of its option to purchase additional shares. The total
net proceeds of the offering are approximately $5.9 million after
deducting the underwriting discounts and commissions payable by
Histogenics.
Canaccord Genuity acted as the sole book-running
manager for the offering.
A shelf registration statement on Form S-3 (File
No. 333-216741) relating to the underwritten registered direct
offering of the shares of common stock described above was filed
with the Securities and Exchange Commission (the SEC) and declared
effective by the SEC on March 30, 2017. A final prospectus
supplement and accompanying prospectus relating to and describing
the terms of the offering was filed with the SEC on January 24,
2018 and is available on the SEC’s web site at www.sec.gov. Copies
of the prospectus supplement and accompanying prospectus relating
to these securities may also be obtained by sending a request to
Canaccord Genuity Inc., Attention: Syndicate Department, 99 High
Street, 12th Floor, Boston, Massachusetts 02110, by telephone at
(617) 371-3900, or by email at prospectus@canaccordgenuity.com.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the
development of restorative cell therapies that may offer
rapid-onset pain relief and restored function. Histogenics’
lead investigational product, NeoCart, is designed to rebuild a
patient’s own knee cartilage to treat pain at the source and
potentially prevent a patient’s progression to
osteoarthritis. NeoCart is one of the most rigorously studied
restorative cell therapies for orthopedic use. Histogenics
recently completed enrollment of its NeoCart Phase 3 clinical trial
and expects to report top-line, one-year superiority data in the
third quarter of 2018. NeoCart is designed to perform like
articular hyaline cartilage at the time of treatment, and as a
result, may provide patients with more rapid pain relief and
accelerated recovery as compared to the current standard of care.
Histogenics’ technology platform has the potential to be used for a
broad range of additional restorative cell therapy
indications.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Apr 2023 to Apr 2024